Patents by Inventor Nadia Brugger

Nadia Brugger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as type II IRAK inhibitors
    Patent number: 11873303
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: January 16, 2024
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Nadia Brugger, Theresa Johnson
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20230303514
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 28, 2023
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 11629134
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: December 19, 2020
    Date of Patent: April 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 11512069
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: November 29, 2022
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210300940
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 30, 2021
    Applicant: Merck Patent GmbH
    Inventors: Brian Sherer, Ruoxi Lan, Nadia Brugger, Xiaoling Chen, Momar Toure, Esther Cleary, Lizbeth Celeste Deselm, Yanping Wang
  • HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF
    Publication number: 20210163487
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: April 1, 2019
    Publication date: June 3, 2021
    Inventors: Catherine JORAND-LEBRUN, Nadia BRUGGER, Theresa JOHNSON
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210115013
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: December 19, 2020
    Publication date: April 22, 2021
    Inventors: Brian A. SHERER, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947213
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • TLR7/8 antagonists and uses thereof
    Patent number: 10947214
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: March 16, 2021
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002256
    Abstract: A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. Sherer, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210002255
    Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Inventors: Brian A. SHERER, Xiaoling Chen, Esther Cleary, Nadia Brugger
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20200369648
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 26, 2020
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • TLR7/8 antagonists and uses thereof
    Patent number: 10836750
    Abstract: Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: November 17, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • TLR7/8 antagonists and uses thereof
    Patent number: 10793553
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 6, 2020
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger, Ruoxi Lan, Xiaoling Chen
  • Display screen or portion thereof with graphical user interface
    Patent number: D962258
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 30, 2022
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener
  • Display screen or portion thereof with graphical user interface
    Patent number: D962259
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 30, 2022
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener
  • Display screen or portion thereof with graphical user interface
    Patent number: D962260
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 30, 2022
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener
  • Display screen or portion thereof with graphical user interface
    Patent number: D962282
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: August 30, 2022
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener
  • Display screen or portion thereof with graphical user interface
    Patent number: D970517
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: November 22, 2022
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener
  • Display screen or portion thereof with graphical user interface
    Patent number: D980235
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: March 7, 2023
    Assignees: Sigma-Aldrich Co. LLC, EMD Millipore Corporation
    Inventors: Sarah Trice, Lindsey Rickershauser, Xiang Wu, Churl Oh, Nadia Brugger, Emma Gardener